3billion Inc.
KOSDAQ-listed genomic diagnostics company offering AI-driven rare-disease genetic testing and the GEBRA interpretation software.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2016 and listed on KOSDAQ in 2024, 3billion is a rare-disease genetic diagnostics company built on AI technology. It provides WGS (whole genome sequencing) and WES (whole exome sequencing)-based rare-disease diagnostic testing as Full service, data-based diagnostic testing, and disease-specific diagnostic testing, and launched its genetic variant interpretation software GEBRA as a SaaS product in April 2025. It generates revenue in 75 countries, achieving KRW 11.7 billion in revenue in 2025 (67.4% overseas), established its US subsidiary 3billion US, Inc. in October 2025, and employs 52 R&D staff, or 51.5% of its total workforce.
Products & technology
- Full serviceEnd-to-end rare disease genetic testing from sample collection through sequencing, interpretation, and reporting
- Data-based diagnostic testRare disease diagnostic testing excluding sample collection and sequencing
- Disease-specific diagnostic testDiagnostic testing for a specific disease and related disease groups
- GEBRASaaS software for genetic variant interpretation
Regulatory approvals
data.go.kr1 Korean MFDS device approvals · 2020
- MFDSTool for specimens2020-09-07Product approval · Class 1수신 20-2118 호
R&D and key agreements
Source: DART corporate disclosureAI 신약개발 플랫폼 · 다양한 질환(신규타겟 발굴 등) · 전임상 단계 검증 · Target discovery, binding pocket discovery, and hit compound exploration; aims for licensing-out to pharma partners for joint clinical development
Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.
Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.
KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.
Ensol Biosciences is a KONEX-listed biotech developing short peptide therapeutics that modulate protein-protein interactions (PPI).
KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.
Alpha AI, founded in 1995 and KOSDAQ-listed in 2000, manufactures biocompatible metal implants and surgical instruments.
CTC Bio develops veterinary and human medicines using fermentation and drug-delivery technology, including CTCZYME and a CBD oral film.
Founded in 2011 and KOSDAQ-listed in 2019, Sugentech develops multiplex immunoblot, point-of-care, and digital healthcare diagnostics.
GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.
KOSDAQ-listed in-vitro diagnostics company developing the LabChip-based VERI-Q molecular diagnostic device series.
Xcell Therapeutics develops the domestically produced CellCor™ cell culture media series for cell and gene therapy manufacturing.
Holds manufacturing approvals for 42 point-of-care diagnostic reagents and devices in the IVD market.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition